• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

Section Contents Menu

Vaccines

Identity Test Results Memo, May 6, 2010 - MenHibrix

MEMORANDUM

Date:         06 May, 2010       

To:            STN # 125363

From:        Manju Joshi, HFM-407

Through:   Rajesh K. Gupta, HFM-407
                    William McCormick, HFM-407

Subject:     Identity Test results on Final Container, STN 125363: MenHiberix® (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine: Hib-MenCY-TT), GlaxoSmithKline Biologicals

CC:           Joseph Temenak, HFM-481
                  David Staten, HFM-475
__________________________________________________________________________
GSK submitted (b)(4) lots of combined Hib-MenCY-TT conjugate vaccine (final container) for testing in support of the Biologics License Application (BLA). Identity test for MenC-TT and MenY-TT conjugates was performed using a method adopted from the manufacturer’s method [SOP 9000010628: Translation of procedure 9000003114-version 07: Identity (PSC-TT and PSY-TT) in conjugated (b)(4) and final containers by (b)(4)] and for Hib-TT conjugate was performed using a method adopted from the manufacturer’s method (SOP 9000007241: Translation of procedure 9000001118-version 06: Determination of the conjugate (PSTT) of Haemophilus influenzae type B by -(b)(4)- ). Below are results of identity test performed at CBER.

 

Product

 

Lot Number

 

Identity Test Results

 

 

Hib-TT

MenC-TT

MenY-TT

Hib-MenCY-TT

----(b)(4)----

Positive

Positive

Positive

Hib-MenCY-TT

----(b)(4)----

Positive

Positive

Positive

Hib-MenCY-TT

----(b)(4)----

Positive

Positive

Positive

 

 

 

 

 

 

The results for all the lots tested meet specifications for the identity test.